These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 25384431

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system.
    Muller ME, Forni Ogna V, Maillard M, Stoudmann C, Zweiacker C, Anex C, Wuerzner G, Burnier M, Bonny O.
    Pflugers Arch; 2015 Dec; 467(12):2413-21. PubMed ID: 26089029
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
    Kazama JJ, Omori K, Higuchi N, Takahashi N, Ito Y, Maruyama H, Narita I, Cantor TL, Gao P, Gejyo F.
    Nephrol Dial Transplant; 2004 Apr; 19(4):892-7. PubMed ID: 15031346
    [Abstract] [Full Text] [Related]

  • 7. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K, Quarles D, Kubo Y, Tomlin H, Goodman W.
    Nephron Clin Pract; 2012 Apr; 121(3-4):c124-30. PubMed ID: 23208191
    [Abstract] [Full Text] [Related]

  • 8. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ.
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW.
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [Abstract] [Full Text] [Related]

  • 14. Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients.
    Jean G, Souberbielle JC, Zaoui E, Lorriaux C, Hurot JM, Mayor B, Deleaval P, Mehdi M, Chazot C.
    BMC Nephrol; 2016 Oct 18; 17(1):153. PubMed ID: 27756251
    [Abstract] [Full Text] [Related]

  • 15. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L, Ngueyon Sime W, Filipozzi P, Nomine-Criqui C, Aronova A, Zarnegar R, Kessler M, Frimat L, Ayav C.
    Surgery; 2016 Jan 18; 159(1):183-91. PubMed ID: 26476826
    [Abstract] [Full Text] [Related]

  • 16. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC, Lin YC, Hsu CY, Kao CC, Chang FC, Chen TW, Chen HH, Hsu CC, Wu MS, Taiwan Society of Nephrology.
    PLoS One; 2015 Jan 18; 10(6):e0129737. PubMed ID: 26107510
    [Abstract] [Full Text] [Related]

  • 17. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
    Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M.
    PLoS One; 2018 Jan 18; 13(4):e0195316. PubMed ID: 29614098
    [Abstract] [Full Text] [Related]

  • 18. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F, Meeus G, Dratwa M, Maes B, Vanholder R, Albert A, Schutyser E, Jadoul M.
    Acta Clin Belg; 2013 Jan 18; 68(4):275-81. PubMed ID: 24455797
    [Abstract] [Full Text] [Related]

  • 19. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.
    Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S, KRN1493 study group.
    Nephrol Dial Transplant; 2008 Jan 18; 23(1):328-35. PubMed ID: 17717030
    [Abstract] [Full Text] [Related]

  • 20. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU.
    J Ren Nutr; 2006 Jul 18; 16(3):253-8. PubMed ID: 16825031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.